{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:39:15Z","timestamp":1791599955324,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH- F2-2010-242114"],"award-info":[{"award-number":["HEALTH- F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early response to first-line antipsychotic treatments is strongly associated with positive long-term symptomatic and functional outcome in psychosis. Unfortunately, attempts to identify reliable predictors of treatment response in first-episode psychosis (FEP) patients have not yet been successful. One reason for this could be that FEP patients are highly heterogeneous in terms of symptom expression and underlying disease biological mechanisms, thereby impeding the identification of one-size-fits-all predictors of treatment response. We have used a clustering approach to stratify 325 FEP patients into four clinical subtypes, termed C1A, C1B, C2A and C2B, based on their symptoms assessed using the Positive and Negative Syndrome Scale (PANSS) scale. Compared to C1B, C2A and C2B patients, those from the C1A subtype exhibited the most severe symptoms and were the most at risk of being non-remitters when treated with the second-generation antipsychotic drug amisulpride. Before treatment, C1A patients exhibited higher serum levels of several pro-inflammatory cytokines and inflammation-associated biomarkers therefore validating our stratification approach on external biological measures. Most importantly, in the C1A subtype, but not others, lower serum levels of interleukin (IL)-15, higher serum levels of C-X-C motif chemokine 12 (CXCL12), previous exposure to cytomegalovirus (CMV), use of recreational drugs and being younger were all associated with higher odds of being non-remitters 4 weeks after treatment. The predictive value of this model was good (mean area under the curve (AUC)\u2009=\u20090.73\u2009\u00b1\u20090.10), and its specificity and sensitivity were 45\u2009\u00b1\u20090.09% and 83\u2009\u00b1\u20090.03%, respectively. Further validation and replication of these results in clinical trials would pave the way for the development of a blood-based assisted clinical decision support system in psychosis.<\/jats:p>","DOI":"10.1038\/s41398-018-0366-5","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T17:03:43Z","timestamp":1547744623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study"],"prefix":"10.1038","volume":"9","author":[{"given":"Emanuela","family":"Martinuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-9253","authenticated-orcid":false,"given":"Douglas","family":"Daoudlarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Bel Haj Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyprien","family":"Gilet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Fillatre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfa","family":"Khalfallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9jane","family":"Troudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4321-4100","authenticated-orcid":false,"given":"St\u00e9phane","family":"Jamain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Fond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Dazzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Covadonga M.","family":"Diaz-Caneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 Sylvain","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yolken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shon","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-4835","authenticated-orcid":false,"given":"Richard","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Davidovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Leboyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Glaichenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the OPTiMiSE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"366_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae), 5th edn (American Psychiatric Publishing, Arlington, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"Suppl 12","key":"366_CR2","first-page":"5","volume":"64","author":"J Kane","year":"2003","unstructured":"Kane, J., Leucht, S., Carpenter, D. & Docherty, J., Disorders, E.C.P.f.O.P.T.o.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry 64 (Suppl 12), 5\u201319 (2003).","journal-title":"J. Clin. Psychiatry"},{"key":"366_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.mp.4002136","volume":"14","author":"S Leucht","year":"2009","unstructured":"Leucht, S., Arbter, D., Engel, R. R., Kissling, W. & Davis, J. M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14, 429\u2013447 (2009).","journal-title":"Mol. Psychiatry"},{"key":"366_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1001\/jama.2013.8804","volume":"310","author":"JA Lieberman","year":"2013","unstructured":"Lieberman, J. A., Dixon, L. B. & Goldman, H. H. Early detection and intervention in schizophrenia: a new therapeutic model. JAMA 310, 689\u2013690 (2013).","journal-title":"JAMA"},{"key":"366_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1176\/appi.ajp.2014.14111465","volume":"172","author":"LB Dixon","year":"2015","unstructured":"Dixon, L. B. & Stroup, T. S. Medications for first-episode psychosis: making a good start. Am. J. Psychiatry 172, 209\u2013211 (2015).","journal-title":"Am. J. Psychiatry"},{"key":"366_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/schbul\/sbv002","volume":"41","author":"G Fond","year":"2015","unstructured":"Fond, G. et al. The promise of biological markers for treatment response in first- episode psychosis: a systematic review. Schizophr. Bull. 41, 559\u2013573 (2015).","journal-title":"Schizophr. Bull."},{"key":"366_CR7","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4088\/JCP.v67n1120","volume":"67","author":"S Leucht","year":"2006","unstructured":"Leucht, S. & Kane, J. M. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J. Clin. Psychiatry 67, 1813\u20131814 (2006).","journal-title":"J. Clin. Psychiatry"},{"key":"366_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen, N. C. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441\u2013449 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"366_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/15622970701541054","volume":"10","author":"M Jager","year":"2009","unstructured":"Jager, M. et al. Prediction of symptom remission in schizophrenia during inpatient treatment. World J. Biol. Psychiatry 10, 426\u2013434 (2009).","journal-title":"World J. Biol. Psychiatry"},{"key":"366_CR10","doi-asserted-by":"publisher","first-page":"e1441","DOI":"10.4088\/JCP.13m08863","volume":"76","author":"M Parellada","year":"2015","unstructured":"Parellada, M. et al. Predictors of functional and clinical outcome in early-onset first-episode psychosis: the child and adolescent first episode of psychosis (CAFEPS) study. J. Clin. Psychiatry 76, e1441\u2013e1448 (2015).","journal-title":"J. Clin. Psychiatry"},{"key":"366_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.31887\/DCNS.2005.7.1\/kdean","volume":"7","author":"K Dean","year":"2005","unstructured":"Dean, K. & Murray, R. M. Environmental risk factors for psychosis. Dialog. Clin. Neurosci. 7, 69\u201380 (2005).","journal-title":"Dialog. Clin. Neurosci."},{"key":"366_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1176\/appi.ajp.163.3.521","volume":"163","author":"WW Eaton","year":"2006","unstructured":"Eaton, W. W. et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 163, 521\u2013528 (2006).","journal-title":"Am. J. Psychiatry"},{"key":"366_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/mp.2008.5","volume":"13","author":"RH Yolken","year":"2008","unstructured":"Yolken, R. H. & Torrey, E. F. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 13, 470\u2013479 (2008).","journal-title":"Mol. Psychiatry"},{"key":"366_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00406-004-0481-6","volume":"254","author":"FM Leweke","year":"2004","unstructured":"Leweke, F. M. et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254, 4\u20138 (2004).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"366_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/schbul\/sbm139","volume":"34","author":"DW Niebuhr","year":"2008","unstructured":"Niebuhr, D. W., Millikan, A. M., Yolken, R., Li, Y. & Weber, N. S. Results from a hypothesis generating case-control study: herpes family viruses and schizophrenia among military personnel. Schizophr. Bull. 34, 1182\u20131188 (2008).","journal-title":"Schizophr. Bull."},{"key":"366_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","volume":"63","author":"S Potvin","year":"2008","unstructured":"Potvin, S. et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63, 801\u2013808 (2008).","journal-title":"Biol. Psychiatry"},{"key":"366_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller, B. J., Buckley, P., Seabolt, W., Mellor, A. & Kirkpatrick, B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70, 663\u2013671 (2011).","journal-title":"Biol. Psychiatry"},{"key":"366_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","volume":"155","author":"R Upthegrove","year":"2014","unstructured":"Upthegrove, R., Manzanares-Teson, N. & Barnes, N. M. Cytokine function in medication-naive first episode psychosis: a systematic review and meta- analysis. Schizophr. Res. 155, 101\u2013108 (2014).","journal-title":"Schizophr. Res."},{"key":"366_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00213-011-2392-3","volume":"219","author":"B Crespo-Facorro","year":"2012","unstructured":"Crespo-Facorro, B. et al. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl.) 219, 225\u2013233 (2012).","journal-title":"Psychopharmacology (Berl.)"},{"issue":"Suppl. 1","key":"366_CR20","first-page":"S153","volume":"24","author":"A Kubistova","year":"2012","unstructured":"Kubistova, A., Horacek, J. & Novak, T. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr. Danub. 24 (Suppl. 1), S153\u2013S156 (2012).","journal-title":"Psychiatr. Danub."},{"key":"366_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1017\/S1461145711001775","volume":"16","author":"KS MacDowell","year":"2013","unstructured":"MacDowell, K. S. et al. Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int. J. Neuropsychopharmacol. 16, 121\u2013135 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"366_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","volume":"154","author":"L de Witte","year":"2014","unstructured":"de Witte, L. et al. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr. Res. 154, 23\u201329 (2014).","journal-title":"Schizophr. Res."},{"key":"366_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pnpbp.2014.01.001","volume":"51","author":"M Ding","year":"2014","unstructured":"Ding, M. et al. Activation of Th17 cells in drug naive, first episode schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 51, 78\u201382 (2014).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"366_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbv019","volume":"41","author":"S Leucht","year":"2015","unstructured":"Leucht, S. et al. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr. Bull. 41, 549\u2013558 (2015).","journal-title":"Schizophr. Bull."},{"key":"366_CR25","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn, R. S. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085\u20131097 (2008).","journal-title":"Lancet"},{"key":"366_CR26","volume-title":"Clinical Global Impression, ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy, W. Clinical Global Impression, ECDEU Assessment Manual for Psychopharmacology (National Institute of Mental Health, Rockville, 1976)."},{"key":"366_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","volume":"3","author":"D Addington","year":"1990","unstructured":"Addington, D., Addington, J. & Schissel, B. A depression rating scale for schizophrenics. Schizophr. Res. 3, 247\u2013251 (1990).","journal-title":"Schizophr. Res."},{"key":"366_CR28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S. & Pioli, R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 101, 323\u2013329 (2000).","journal-title":"Acta Psychiatr. Scand."},{"key":"366_CR29","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1001\/archpsyc.58.11.1032","volume":"58","author":"SL Buka","year":"2001","unstructured":"Buka, S. L. et al. Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 58, 1032\u20131037 (2001).","journal-title":"Arch. Gen. Psychiatry"},{"key":"366_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2005","unstructured":"Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. J. R. Stat. Soc. B 67, 301\u2013320 (2005).","journal-title":"J. R. Stat. Soc. B"},{"key":"366_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpsychires.2016.03.016","volume":"78","author":"R Iniesta","year":"2016","unstructured":"Iniesta, R. et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J. Psychiatr. Res. 78, 94\u2013102 (2016).","journal-title":"J. Psychiatr. Res."},{"key":"366_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.patrec.2005.10.010","volume":"27","author":"T Fawcett","year":"2006","unstructured":"Fawcett, T. An introduction to ROC analysis. Pattern Recognit. Lett. 27, 861\u2013874 (2006).","journal-title":"Pattern Recognit. Lett."},{"key":"366_CR33","unstructured":"R Core Team. A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing:, Vienna, 2016)."},{"key":"366_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn, M. Caret package. J. Stat. Softw. 28, 1\u201326 (2008).","journal-title":"J. Stat. Softw."},{"key":"366_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"key":"366_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).","journal-title":"BMC Bioinforma."},{"key":"366_CR37","doi-asserted-by":"crossref","unstructured":"Candia, J. & Tsang, J. S. eNetXplorer: an R package for the quantitative exploration of elastic net families for generalized linear models (April 30, 2018).","DOI":"10.1101\/305870"},{"key":"366_CR38","unstructured":"Gilet, C., Deprez, M., Caillau, J.-B. & Barlaud, M. Clustering with feature selection using alternating minimization. Application to computational biology. Published 2017 in ArXiv."},{"key":"366_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","volume":"5","author":"RS Kahn","year":"2018","unstructured":"Kahn, R. S. et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 5, 797\u2013807 (2018).","journal-title":"Lancet Psychiatry"},{"key":"366_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/14789450.2018.1444483","volume":"15","author":"RL Preece","year":"2018","unstructured":"PreeceR. L., Han, S. Y. S. & Bahn, S. Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders. Expert Rev. Proteomics 15, 325\u2013340 (2018).","journal-title":"Expert Rev. Proteomics"},{"key":"366_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"366_CR42","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1017\/S0033291716001367","volume":"46","author":"R Iniesta","year":"2016","unstructured":"Iniesta, R., Stahl, D. & McGuffin, P. Machine learning, statistical learning and the future of biological research in psychiatry. Psychol. Med. 46, 2455\u20132465 (2016).","journal-title":"Psychol. Med."},{"key":"366_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.bpsc.2016.04.002","volume":"1","author":"AF Marquand","year":"2016","unstructured":"Marquand, A. F., Wolfers, T., Mennes, M., Buitelaar, J. & Beckmann, C. F. Beyond lumping and splitting: a review of computational approaches for stratifying psychiatric disorders. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 1, 433\u2013447 (2016).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"366_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bpsc.2017.11.007","volume":"3","author":"D Bzdok","year":"2018","unstructured":"Bzdok, D. & Meyer-Lindenberg, A. Machine learning for precision psychiatry: opportunities and challenges. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 3, 223\u2013230 (2018).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"366_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.euroneuro.2013.09.010","volume":"24","author":"G Schumann","year":"2014","unstructured":"Schumann, G. et al. Stratified medicine for mental disorders. Eur. Neuropsychopharmacol. 24, 5\u201350 (2014).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"366_CR46","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.biopsych.2014.09.017","volume":"77","author":"P Chaste","year":"2015","unstructured":"Chaste, P. et al. A genome-wide association study of autism using the Simons Simplex Collection: does reducing phenotypic heterogeneity in autism increase genetic homogeneity? Biol. Psychiatry 77, 775\u2013784 (2015).","journal-title":"Biol. Psychiatry"},{"key":"366_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aab2358","volume":"348","author":"TR Insel","year":"2015","unstructured":"Insel, T. R. & Cuthbert, B. N. Medicine. Brain disorders? Precisely. Science 348, 499\u2013500 (2015).","journal-title":"Science"},{"key":"366_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2105\/AJPH.2007.126847","volume":"98","author":"A Steckler","year":"2008","unstructured":"Steckler, A. & McLeroy, K. R. The importance of external validity. Am. J. Public Health 98, 9\u201310 (2008).","journal-title":"Am. J. Public Health"},{"key":"366_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-1781(83)90132-4","volume":"8","author":"AE Farmer","year":"1983","unstructured":"Farmer, A. E., McGuffin, P. & Spitznagel, E. L. Heterogeneity in schizophrenia: a cluster-analytic approach. Psychiatry Res. 8, 1\u201312 (1983).","journal-title":"Psychiatry Res."},{"key":"366_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1017\/S0033291700026817","volume":"24","author":"DJ Castle","year":"1994","unstructured":"Castle, D. J., Sham, P. C., Wessely, S. & Murray, R. M. The subtyping of schizophrenia in men and women: a latent class analysis. Psychol. Med. 24, 41\u201351 (1994).","journal-title":"Psychol. Med."},{"key":"366_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/schbul\/22.3.545","volume":"22","author":"S Dollfus","year":"1996","unstructured":"Dollfus, S. et al. Identifying subtypes of schizophrenia by cluster analyses. Schizophr. Bull. 22, 545\u2013555 (1996).","journal-title":"Schizophr. Bull."},{"key":"366_CR52","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/archpsyc.55.6.492","volume":"55","author":"KS Kendler","year":"1998","unstructured":"Kendler, K. S., Karkowski, L. M. & Walsh, D. The structure of psychosis: latent class analysis of probands from the Roscommon Family Study. Arch. Gen. Psychiatry 55, 492\u2013499 (1998).","journal-title":"Arch. Gen. Psychiatry"},{"key":"366_CR53","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1017\/S0033291704003745","volume":"35","author":"V Murray","year":"2005","unstructured":"Murray, V. et al. Dimensions and classes of psychosis in a population cohort: a four-class, four-dimension model of schizophrenia and affective psychoses. Psychol. Med. 35, 499\u2013510 (2005).","journal-title":"Psychol. Med."},{"key":"366_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/schbul\/sbr125","volume":"39","author":"MD Bell","year":"2013","unstructured":"Bell, M. D., Corbera, S., Johannesen, J. K., Fiszdon, J. M. & Wexler, B. E. Social cognitive impairments and negative symptoms in schizophrenia: are there subtypes with distinct functional correlates? Schizophr. Bull. 39, 186\u2013196 (2013).","journal-title":"Schizophr. Bull."},{"key":"366_CR55","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel, T. et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167, 748\u2013751 (2010).","journal-title":"Am. J. Psychiatry"},{"key":"366_CR56","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","volume":"71","author":"W Laan","year":"2010","unstructured":"Laan, W. et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo- controlled trial. J. Clin. Psychiatry 71, 520\u2013527 (2010).","journal-title":"J. Clin. Psychiatry"},{"key":"366_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-74","volume":"11","author":"M Berk","year":"2013","unstructured":"Berk, M. et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 11, 74 (2013).","journal-title":"BMC Med."},{"key":"366_CR58","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/187152809789352221","volume":"8","author":"M Berthold-Losleben","year":"2009","unstructured":"Berthold-Losleben, M., Heitmann, S. & Himmerich, H. Anti-inflammatory drugs in psychiatry. Inflamm. Allergy Drug. Targets 8, 266\u2013276 (2009).","journal-title":"Inflamm. Allergy Drug. Targets"},{"key":"366_CR59","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4088\/JCP.10r06823","volume":"73","author":"IE Sommer","year":"2012","unstructured":"Sommer, I. E., de Witte, L., Begemann, M. & Kahn, R. S. Nonsteroidal anti- inflammatory drugs in schizophrenia: ready for practice or a good start? A meta- analysis. J. Clin. Psychiatry 73, 414\u2013419 (2012).","journal-title":"J. Clin. Psychiatry"},{"key":"366_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/schbul\/sbt139","volume":"40","author":"IE Sommer","year":"2014","unstructured":"Sommer, I. E. et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 40, 181\u2013191 (2014).","journal-title":"Schizophr. Bull."},{"key":"366_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/acps.12211","volume":"129","author":"G Fond","year":"2014","unstructured":"Fond, G. et al. Effectiveness and tolerance of anti-inflammatory drugs\u2019 add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr. Scand. 129, 163\u2013179 (2014).","journal-title":"Acta Psychiatr. Scand."},{"key":"366_CR62","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.4088\/JCP.14f09292","volume":"75","author":"C Andrade","year":"2014","unstructured":"Andrade, C. Nonsteroidal anti-inflammatory drugs and 5-HT(3) serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia. J. Clin. Psychiatry 75, e707\u2013e709 (2014).","journal-title":"J. Clin. Psychiatry"},{"key":"366_CR63","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","volume":"39","author":"M Nitta","year":"2013","unstructured":"Nitta, M. et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr. Bull. 39, 1230\u20131241 (2013).","journal-title":"Schizophr. Bull."},{"key":"366_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pnpbp.2012.11.008","volume":"42","author":"N Muller","year":"2013","unstructured":"Muller, N., Myint, A. M., Krause, D., Weidinger, E. & Schwarz, M. J. Anti- inflammatory treatment in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 146\u2013153 (2013).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"366_CR65","doi-asserted-by":"publisher","first-page":"abstr S314","DOI":"10.1038\/npp.2012.221","volume":"38","author":"M Weiser","year":"2012","unstructured":"Weiser, M., Burshtein, S. & L, F. A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology 38, abstr S314\u2013S446 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"366_CR66","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1176\/ajp.152.9.1291","volume":"152","author":"CG McAllister","year":"1995","unstructured":"McAllister, C. G. et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 152, 1291\u20131297 (1995).","journal-title":"Am. J. Psychiatry"},{"key":"366_CR67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","volume":"32","author":"A Lin","year":"1998","unstructured":"Lin, A. et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32, 9\u201315 (1998).","journal-title":"Schizophr. Res."},{"key":"366_CR68","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/sj.npp.1300756","volume":"30","author":"XY Zhang","year":"2005","unstructured":"Zhang, X. Y., Zhou, D. F., Cao, L. Y., Wu, G. Y. & Shen, Y. C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30, 1532\u20131538 (2005).","journal-title":"Neuropsychopharmacology"},{"key":"366_CR69","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","volume":"41","author":"V Mondelli","year":"2015","unstructured":"Mondelli, V. et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 41, 1162\u20131170 (2015).","journal-title":"Schizophr. Bull."},{"key":"366_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1074-7613(00)80664-0","volume":"9","author":"JP Lodolce","year":"1998","unstructured":"Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669\u2013676 (1998).","journal-title":"Immunity"},{"key":"366_CR71","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.immuni.2009.09.017","volume":"31","author":"E Mortier","year":"2009","unstructured":"Mortier, E. et al. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 31, 811\u2013822 (2009).","journal-title":"Immunity"},{"key":"366_CR72","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/glia.20628","volume":"56","author":"D Gomez-Nicola","year":"2008","unstructured":"Gomez-Nicola, D., Valle-Argos, B., Pita-Thomas, D. W. & Nieto-Sampedro, M. Interleukin 15 expression in the CNS: blockade of its activity prevents glial activation after an inflammatory injury. Glia 56, 494\u2013505 (2008).","journal-title":"Glia"},{"key":"366_CR73","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1091\/mbc.e11-01-0053","volume":"22","author":"D Gomez-Nicola","year":"2011","unstructured":"Gomez-Nicola, D., Valle-Argos, B., Pallas-Bazarra, N. & Nieto-Sampedro, M. Interleukin-15 regulates proliferation and self-renewal of adult neural stem cells. Mol. Biol. Cell. 22, 1960\u20131970 (2011).","journal-title":"Mol. Biol. Cell."},{"key":"366_CR74","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.psyneuen.2010.07.017","volume":"36","author":"X Wu","year":"2011","unstructured":"Wu, X. et al. Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Ralpha receptor. Psychoneuroendocrinology 36, 266\u2013278 (2011).","journal-title":"Psychoneuroendocrinology"},{"key":"366_CR75","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neubiorev.2012.11.009","volume":"37","author":"W Pan","year":"2013","unstructured":"Pan, W. et al. Brain interleukin-15 in neuroinflammation and behavior. Neurosci. Biobehav. Rev. 37, 184\u2013192 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"366_CR76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fncel.2014.00115","volume":"5","author":"A Guyon","year":"2014","unstructured":"Guyon, A. CXCL12 chemokine and GABA neurotransmitter systems crosstalk and their putative roles. Front. Cell. Neurosci. 5, 115 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"366_CR77","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00023210-200620110-00001","volume":"20","author":"EF Torrey","year":"2006","unstructured":"Torrey, E. F. et al. Cytomegalovirus and schizophrenia. CNS Drugs 20, 879\u2013885 (2006).","journal-title":"CNS Drugs"},{"key":"366_CR78","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","volume":"264","author":"DA Regier","year":"1990","unstructured":"Regier, D. A. et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264, 2511\u20132518 (1990).","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1038\/s41398-019-0505-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000}}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0366-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0366-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0366-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:18:47Z","timestamp":1671203927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0366-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1038\/s41398-018-0366-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41398-019-0505-7","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original Article did not feature the list of collaborators. This has now been corrected in the PDF and HTML versions of this Article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"20"}}